Rouzade‐Dominguez, Marie‐Laure
Novartis (Switzerland)
2 papers on CoChat
Most cited papers
- Verified
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 177
- Verified
The Alzheimer’s Prevention Initiative Generation Program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer’s disease
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 116
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free